Universal Society for Pharmacoeconomics and Outcomes Research

0
0
1562 days ago, 551 views
PowerPoint PPT Presentation

Presentation Transcript

Slide 1

Global Society for Pharmacoeconomics and Outcomes Research

Slide 2

Chris L Pashos, PhD ISPOR President, 2008-2009

Slide 3

ISPOR SRBIJA

Slide 4

Belgrade, Serbia

Slide 5

WELCOME DOBRODO š LI ISPOR SRBIJA 1 ST INTERNATIONAL CONFERENCE

Slide 6

President Vladimir Zah, K.S. B.Sc., Health Economics Consultant, Belgrade Vice-President Tanja Novakovic, MSc Pharm., Galenika a.d., President of Pharmacoeconomic Section of Pharmaceutical Society of Serbia (FDS), Belgrade Secretary/Treasurer Dr sci. ph. spec Natasa Bogavac-Stanojevic, Assoc. Educator, Faculty of Pharmacy, University of Belgrade

Slide 7

Directors Dr sci. med. Ana Sabo , Professor, Medical Faculty, University of Novi Sad Dr Predrag Djukic , Consultant, Project Coordination Unit, Ministry of Health, Belgrade Dr Dragana Atanasijevic , Consultant Project Coordination Unit, Ministry of Health, Belgrade Doc.dr sci.ph Vesela Radonjic , Director, National Information Center for Medicine and Medical Devices (ALIMS), Belgrade Mr ph Danka Stefanovic , ALIMS, Belgrade Mr ph Danka Tesic , ALIMS, Belgrade Mr ph spec. Dragana Sovtic , Independent consultant for pharmaceutical issues, The Pharmaceutical Chamber of Serbia

Slide 8

ISPOR A universal, instructive and logical association that encourages perfection in pharmacoeconomics and results explore and the fitting utilization of coming about data in medicinal services choices at all levels to advance the general wellbeing and prosperity

Slide 9

OUR MISSION To advance the art of pharmacoeconomics and results research To encourage the interpretation of this examination into valuable data for human services leaders To guarantee that society apportions rare assets shrewdly, decently, and proficiently RESEARCH  EVIDENCE  DECISIONS  HEALTH

Slide 10

Who we are Where we are going How we will arrive

Slide 11

OUR SCOPE MULTI-DISCIPLINARY Decision Analysis, Economics, Epidemiology, Modeling, Patient Reported Outcomes Assessment, Real World Data Analysis, Risk Assessment INCLUSIVE Decision Makers, Health Care Providers, Researchers, Students GEOGRAPHICALLY DIVERSE

Slide 12

Over 4200 individuals From 96 nations Who We Are

Slide 13

STUDENT NETWORK Who We Are 40 Student Chapters Worldwide 484 Student Members

Slide 14

Who We Are ISPOR Membership Including Chapters

Slide 15

ISPOR Membership including Chapters Who We Are 2400 ISPOR CHAPTER MEMBERS 4200 ISPOR MEMBERS OVER 6600 WORLDWIDE

Slide 16

Who We Are Asia-Pacific China MDA-PE Hong Kong India Japan Shanghai Taiwan Thailand Australia Under improvement Malaysia South Korea Pakistan Singapore

Slide 17

Who We Are Latin America Argentina Brazil Chile Colombia Mexico Venezuela Under improvement Cuba Ecuador Peru

Slide 18

Who We Are Europe – Middle East Belarus Croatia Czech Republic Greece Hungary Poland Russia Serbia Slovakia Turkey Ukraine Israel Jordan

Slide 19

MEMBERSHIP by Geographic Region Who We Are

Slide 20

MEMBERSHIP by Work Environment Who We Are

Slide 21

Who We Are MEMBERSHIP - WORK ENVIRONMENT Academia Research Groups Health Care Providers Medical Technology Firms Governments

Slide 22

MEMBERSHIP by Research Interests Who We Are

Slide 23

Who We Are MEMBERSHIP – RESEARCH INTERESTS Methods PROs Costs Clinical Outcomes Policy

Slide 24

Who We Are ISPOR – MOVING AHEAD TOGETHER

Slide 25

Where We Are Going Patients (Recipients of Health Care) Patients Health Care Providers FOSTER RESEARCH EXCELLENCE PROMOTE EDUCATION Health Care Payers Health Care Health Care Researchers PROMOTE COLLABORATION WITH DECISION MAKERS STIMULATE INTERNATIONAL GROWTH Regulators & Tech Assessors

Slide 26

What We Do GLOBAL OUTREACH

Slide 27

Athens, Greece - November 2008

Slide 28

MEETINGS IN EUROPE What We Do

Slide 29

What We Do MEETING REGISTRATION: EUROPE

Slide 30

II. Medzinárodná konferencia ISPOR Slovak Chapter Zastúpenie Medzinárodnej spoločnosti pre farmakoekonomiku a klinické výstupy (ISPOR) v Slovenskej republike

Slide 31

MEETINGS IN ASIA AND LATIN AMERICA What We Do

Slide 32

Supporting Research & Practice Globally What We Do

Slide 33

MEETINGS IN NORTH AMERICA What We Do

Slide 34

MEETING REGISTRATION: NORTH AMERICA What We Do

Slide 35

What We Do COLLABORATION TO MOVE THE FIELD FORWARD

Slide 36

What We Do Special Interest Groups Initiated by ISPOR individuals, shaped with a particular research-centered objective. Teams Formed by the Board of Directors for a particular reason, for example, to grow Good Research Practices. Chambers Advisory bodies to ISPOR & its Board of Directors.

Slide 37

What We Do PUBLICATIONS

Slide 38

What We Do PUBLICATIONS

Slide 39

What We Do PUBLICATIONS F u t u r e B o k s

Slide 40

TOOLS What We Do

Slide 41

Tools For Decision-Makers What We Do Global Health Care System Road Map Pharmacoeconomic Guidelines Around the World Managed Care Outcomes Research Digest ISPOR Comments on Health Policy

Slide 42

Global Health Care Systems Road Map Overview of Country Specific Health Systems and Reimbursement Process What We Do

Slide 43

Managed Care Outcomes Research Digest Searchable by administration gave, results evaluated or catchphrase What We Do

Slide 44

Tools For Health Care Researchers What We Do ISPOR Research Digest of International Databases Good Research Practices

Slide 45

ISPOR Research Digest What We Do Electronic database ~9000 examine thinks about from ISPOR gatherings

Slide 46

Digest of International Databases Directory of Databases searchable by key properties What We Do

Slide 47

Good Research Practices What We Do Published articles and reports on multidisciplinary themes

Slide 48

Good Research Practices What We Do Code of Ethics Design and Research Practices Sponsorship Publication and Dissemination Relationship with Others Role of ISPOR

Slide 49

Economic/Pharmacoeconomic Methods Modeling Budget Impact Analysis CEA with Clinical Trials Drug Cost Standards Economic Data Transferability Good Research Practices What We Do

Slide 50

Good Research Practices What We Do Patient Reported Outcomes (PRO) Methods PRO Methods and Concepts Quality of Life Methods Preference-based Methods Population-based Methods Application of Conjoint Analysis in Outcomes Research

Slide 51

Good Research Practices What We Do Real World Methods & Studies Data-based Methods Disease and Health Management Data & Methods Patient Registry Methods Medication Compliance and Persistence Methods & Studies Risk-Benefit Methods

Slide 52

Good Research Practices What We Do Real World Methods & Studies (con " t) Design and Operations of Patient Registries Evaluating Health/Disease Management Programs Patient Registry Classification Strategy & Design Reliability & Validity of Data Sources for Disease & Health Management

Slide 53

Good Research Practices What We Do Medical Devices & Diagnostics Outcomes Research Technology improvement issues Regulatory prerequisites Clinical results explore Economic results look into Patient-reported result inquire about Developing confirmation & repayment issues

Slide 54

HEALTH TECHNOLOGY ASSESSMENT ACTIVITIES What We Do HTA & EVIDENCE-BASED DECISIONS SPECIAL INTEREST GROUP WORKING GROUPS HTA FOR REIMBURSEMENT DECISIONS HTA OF EMERGING NEW TECHNOLOGIES GLOBAL HTA USED IN HC REIMBURSEMENT

Slide 55

HTA ACTIVITIES What We Do Information Roadmap of worldwide medicinal services conveyance & repayment frameworks Directory of HTA associations overall Methods Survey of strategies utilized universally as a part of HTA and arrangement making Translation Survey of procedures for embracing rising advances

Slide 56

HTA ACTIVITIES What We Do ISPOR HTA Council KEY ISSUES Need for information HTA scope & innovation life cycle Methods HTA prioritization Translating data for or by approach creators

Slide 57

Where We Are Going Patients (Recipients of Health Care) Patients Health Care Providers FOSTER RESEARCH EXCELLENCE PROMOTE EDUCATION Health Care Payers Health Care Health Care Researchers PROMOTE COLLABORATION WITH DECISION MAKERS STIMULATE INTERNATIONAL GROWTH Regulators & Tech Assessors

Slide 58

International Society for Pharmacoeconomics and Outcomes Research

Slide 59

3 C ollaboration C ollegiality C ommunication (SR) 2 S cientific R igor S ocietal R elevance

Slide 60

THANK YOU! HVALA!

Slide 61

WELCOME DOBRODO š LI ISPOR SRBIJA 1 ST INTERNATIONAL CONFERENCE

SPONSORS